This $867,712 Project Grant award from the Department of the Army Medical Command (under the Military Medical Research and Development program, CFDA 12.420) supports advanced biomedical research at The Johns Hopkins University focused on transforming healthcare for military service members and the general public. The research aims to investigate effective treatment of pancreatic cancer through systemic chemotherapy combined with alpha-particle radiotherapy, with a focus on early hepatic...
This federal Project Grant award of $610,059.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by The Johns Hopkins University to investigate "The Aging Microenvironment as a Driver of Pancreatic Cancer Metastasis." The award has a performance period from July 1, 2025 to June 30, 2028 and aims to transform healthcare for military service members, veterans, and the general public through innovative biomedical...
This federal Project Grant award from the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) provides $388,194 to The Johns Hopkins University to conduct research on "The Aging Microenvironment as a Driver of Pancreatic Cancer Metastasis." The research aims to transform healthcare for military service members, veterans, and the broader public by investigating innovative medical solutions for critical health challenges. The 3-year project, running from...
The U.S. Defense Health Agency awarded a $776,831 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to The Johns Hopkins University to conduct research on P2 purinergic receptors in pancreatic ductal adenocarcinoma as potential therapeutic targets. The grant, which runs from August 1, 2025 to July 31, 2028, supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. As a leading...
The Johns Hopkins University will receive $620,588 under a three-year Project Grant award from the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420). The grant will fund research to develop a 3D multiscale analysis of malignant progression in human pancreatic cancer. Through September 2025, researchers will investigate medical solutions for pancreatic cancer at the cellular and tissue levels to transform understanding and treatment of this...
This federal Project Grant award of $336,257.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports a pooled mutant KRAS-targeted long peptide vaccine combined with anti-PD-1 and anti-CTLA-4 antibodies for patients with stage IV MMR-P pancreatic ductal adenocarcinoma. The 3-year award, which runs from September 1, 2024 to August 31, 2027, is granted to The Johns Hopkins University, a private non-profit research institution...
This $1,473,750 federal Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports The Johns Hopkins University's research study on "The Immunomodulatory Impact of Chemotherapy When Combined with PD-1 Blockade in Resectable Lung Cancer." The 3-year grant, running from September 1, 2024 to August 31, 2027, aims to investigate innovative immunological interventions for treating lung cancer in military service...
This $1,637,500 federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research conducted by The Johns Hopkins University to target specific PARP1 inhibition for breast cancer treatment. The award, which began on July 1, 2024 and will be completed by June 30, 2027, will enable the university to conduct innovative scientific studies ranging from basic laboratory research to advanced clinical trials focused on improving...
This $484,013 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports the development of "PSMA-TARGETED MULTIPARAMETRIC ULTRASOUND" research at The Johns Hopkins University. The award period runs from August 1, 2024 to July 31, 2026. The project aims to advance biomedical research and innovative medical solutions relevant to military personnel and the broader public. As a leading research institution, The...
This federal Project Grant award of $1,228,021.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) is supporting The Johns Hopkins University in advancing clinical research in ovarian cancer. The grant, awarded on June 1, 2024, will fund the university's efforts to conduct innovative scientific studies and clinical trials over a four-year performance period ending on May 31, 2028. This award enables Johns Hopkins to leverage its expertise...